Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 626 - 650 of 2029 in total

Pexidartinib

Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial...
Approved
Investigational
Matched Description: … tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue. ... Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August ... [A182243] Pexidartinib is available in oral formulations and it is commonly marketed as Turalio. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Alirocumab

Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and statin treatment. It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which...
Approved
Matched Description: … It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class ... high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and ... FDA approval was contingent on the completion of further clinical trials to better determine efficacy and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Abarelix

Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.
Approved
Investigational
Withdrawn
Matched Categories: … Amino Acids, Peptides, and Proteins ... Hormone Antagonists and Related Agents ... Antineoplastic and Immunomodulating Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Lenalidomide

Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of thalidomide and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenalidomide is much safer and potent than thalidomide, with...
Approved
Matched Description: … and toxicities. ... exists as a racemic mixture of the active S(-) and R(+) forms. ... [A228708] However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Tacrine

A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market.
Approved
Investigational
Withdrawn
Matched Description: … in the treatment of Alzheimer's disease and other central nervous system disorders. ... inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and …

Allogeneic processed thymus tissue

Allogeneic processed thymus tissue is used for immune reconstitution in immune disorders where the patients are severely immunocompromised due to the absence of a functional thymus, such as congenital athymia. As part of the immune system, the thymus is an organ responsible for the maturation and selection of T cells...
Approved
Matched Description: … As part of the immune system, the thymus is an organ responsible for the maturation and selection of ... T cells [A239814]; thus, patients without a functional thymus experience profound immunodeficiency and ... [L38929] Congenital athymia is a rare condition that leads to the absence of a thymus at birth and a …

Tizanidine

Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury . It may also be caused by musculoskeletal injury . Regardless of the cause, muscle spasticity can be an...
Approved
Investigational
Matched Description: … Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. …

Ezetimibe

Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal villi - this prompted studies investigating...
Approved
Matched Description: … Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption ... The discovery and research of this drug began in the early 1990s, after the intravenous administration ... [A15202] By interfering with the intestinal uptake of cholesterol and phytosterols, ezetimibe reduces …
Matched Mixtures name: … Ezetimibe and Simvastatin ... Ezetimibe and Simvastatin ... Ezetimibe and Simvastatin …
Matched Categories: … simvastatin and ezetimibe ... pravastatin and ezetimibe ... atorvastatin and ezetimibe ... rosuvastatin and ezetimibe ... bempedoic acid and ezetimibe …

Abiraterone

Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic...
Approved
Matched Description: … ] and September 2011,[A260880] respectively. ... Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17 ... [L40968, L40193, L47740, L47745] As abiraterone has poor oral bioavailability and is susceptible to …
Matched Categories: … niraparib and abiraterone ... abiraterone and prednisolone ... Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... Metabolic Side Effects of Drugs and Substances …

Xylose

Xylose is a monosaccharide of the aldopentose type consisted of five carbon atoms and an aldehyde functional group. Xylose is a sugar isolated from wood. D-Xylose is a sugar widely used as a diabetic sweetener in food and beverage. Xylose has also been used as a diagnostic agent to observe...
Approved
Matched Description: … D-Xylose is a sugar widely used as a diabetic sweetener in food and beverage. ... Xylose is a monosaccharide of the aldopentose type consisted of five carbon atoms and an aldehyde functional ... immediately - but its metabolism results in a variety of substrates that can serve important nutritional and …

Oxaliplatin

Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride...
Approved
Investigational
Matched Description: … refractory to an initial fluorouracil and leucovorin combination. ... Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. ... [A260396] The DACH moiety also prevents cross-resistance with cisplatin and carboplatin. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Fosphenytoin

Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
Approved
Investigational
Matched Description: … channels, and therefore limit repetitive firing of action potentials. ... Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium …
Matched Categories: … Phenytoin and Prodrugs …

Zolpidem

Zolpidem, also known as Ambien, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the...
Approved
Matched Description: … It is available in both immediate acting and extended release forms [FDA label], [F3802]. ... In addition, zolpidem improves sleep quality in patients suffering from chronic insomnia and can show ... Research also shows that zolpidem is rapid and effective in restoring brain function for patients in …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Miscellaneous Anxiolytics Sedatives and Hypnotics …

Hydroxyurea

Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea...
Approved
Matched Description: … adherence, the need for therapeutic monitoring, and serious side effects of secondary cancer and birth ... conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Naloxegol

Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antagonist naloxone is that its...
Approved
Matched Description: … naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and ... It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation …
Matched Categories: … Alimentary Tract and Metabolism …

Azilsartan medoxomil

Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011. Many guidelines...
Approved
Investigational
Matched Description: … , primarily strokes and myocardial infarctions. ... guidelines recommend the use of ARBs as first-line therapy when initiating antihypertensive therapy and ... Lowering blood pressure is associated with a reduced risk of fatal and nonfatal cardiovascular events …
Matched Categories: … azilsartan medoxomil and diuretics ... Angiotensin II receptor blockers (ARBs) and diuretics …

Inulin

A starch found in the tubers and roots of many plants. Since it is hydrolyzable to fructose, it is classified as a fructosan. It has been used in physiologic investigation for determination of the rate of glomerular function.
Approved
Investigational
Nutraceutical
Matched Description: … A starch found in the tubers and roots of many plants. …
Matched Categories: … inulin and other polyfructosans ... Tests for Renal Function and Ureteral Injuries …

Andusomeran

Andusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season.[L40074,L48832,L48837] It is similar to previous mRNA vaccines developed by Moderna (e.g. elasomeran, imelasomeran), but is designed to be effective against the Omicron XBB.1.5 subvariant.
Approved

Palbociclib

Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as...
Approved
Investigational
Matched Description: … electronic health records demonstrating safety and clinical efficacy. ... inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and ... on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Selenomethionine

Selenomethionine is a naturally occuring amino acid in some plant materials such as cereal grains, soybeans and enriched yeast but it cannot be synthesized from animals or humans. It can be produced from post-structural modifications. In vivo, selenomethionine plays an essential role in acting as an antioxidant, where it depletes...
Approved
Investigational
Matched Description: … the inorganic form of selenium, the organic form of selenomethionine is more readily absorbed in the human ... aids in the formation and recycling of glutathione, another important antioxidant. ... Selenomethionine is a naturally occuring amino acid in some plant materials such as cereal grains, soybeans and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Peramivir

Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. Being an influenza virus neuraminidase inhibitor, peramivir works by...
Approved
Investigational
Matched Description: … The development of peramivir has been supported by the US Department of Health and Human Services as ... the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and ... in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and …

Repotrectinib

Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the ROS1 gene. ROS1 mutations are one of the defined oncogenic drives of NSCLC, and the solvent-front mutation ROS1 G2032R is responsible for...
Approved
Investigational
Matched Description: … [A262056] ROS1 mutations are one of the defined oncogenic drives of NSCLC, and the solvent-front mutation ... compact macrocyclic structure that both limits adverse interactions with resistance mutation hotspots and ... resistance to multiple TKI has been reported, including [crizotinib], [lorlatinib], [taletrectinib], and …

Pirtobrutinib

Pirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine kinase (BTK). Its high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of atrial fibrillation. Unlike BTK covalent inhibitors, such as ibrutinib, that bind to the cysteine 481...
Approved
Investigational
Matched Description: … Pirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine ... Its high selectivity has been associated with lower discontinuation rates due to adverse events and a …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Risedronic acid

Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label] .
Approved
Investigational
Matched Description: … acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and …
Matched Categories: … Calcium-Regulating Hormones and Agents ... risedronic acid and colecalciferol ... risedronic acid and calcium, sequential ... Drugs Affecting Bone Structure and Mineralization ... risedronic acid, calcium and colecalciferol, sequential …

Anastrozole

Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such...
Approved
Investigational
Matched Description: … provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and ... drugs of choice in the treatment of postmenopausal breast cancer due to a more favourable efficacy and …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Displaying drugs 626 - 650 of 2029 in total